STAT+

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an Express Scripts lawsuit against FTC, AMR deaths, and more

Pharmalot Ed Silverman

STAT Plus: Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers

Health tech Casey Ross

STAT Plus: A documentary film asks: Can health systems improve patient safety by embracing new tech?

Health tech Mario Aguilar

STAT Plus: What pharma companies and insurers think about Medicare’s plan to cover digital treatments

Who to Know Meghana Keshavan

STAT Plus: 12 people shaping psychedelics drug development

Health tech Katie Palmer

STAT Plus: Most cardiovascular devices with serious safety recalls aren’t tested in patients

Health Care Inc. Bob Herman

STAT Plus: How insurers are covering Humira and copycat medicines

Biotech Andrew Joseph

STAT Plus: After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Top staffer on drug pricing to depart Senate Finance Committee

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more

Biotech Jonathan Wosen

STAT Plus: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending

Biotech Andrew Joseph

STAT Plus: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study 

Biotech Andrew Joseph

STAT Plus: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial

Biotech Andrew Joseph

STAT Plus: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness

Pharma Andrew Joseph

STAT Plus: Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study

Biotech Andrew Joseph

STAT Plus: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharma Jonathan Wosen

STAT Plus: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

Health Jonathan Saltzman — Boston Globe

STAT Plus: ‘I’m still here’: Before Alzheimer’s, he prided himself on his intellect

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more

Politics Mohana Ravindranath

STAT Plus: Why these health tech leaders are making a risky bet, openly backing Trump or Harris

First Opinion Jack Hooper

STAT Plus: What does the presidential election mean for ICHRA and the health insurance market?

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: How efforts to cancel medical debt could wind up benefitting hospitals

Politics Aaron Pressman and Tal Kopan — Boston Globe

STAT Plus: ‘Put him in jail.’ Steward CEO de la Torre skips hearing, now Congress is poised to hold him in contempt

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Can iTeos and GSK solve TIGIT’s troubles?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more

Biotech Elaine Chen

STAT Plus: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial

Biotech Matthew Herper and Jason Mast

STAT Plus: Moderna touts research progress as it cuts R&D spending by $1.1 billion

Biotech Jason Mast and John Wilkerson

STAT Plus: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire